drugset / Trial / NCT04552327

5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis

NCT04552327

RandomizedParallel-groupDouble-blindTreatment

Summary

The KOHDIAK study is a prospective, three-armed, randomised, double-blind study to evaluate the efficacy and safety of the treatment of mild and moderate actinic keratosis with a 5% potassium hydroxide solution (Solcera, medical device) versus placebo and investigator-blinded comparison with 3% diclofenac gel (Solaraze, medicinal product). It is performed in accordance with both the laws in force for clinical trials with medical devices and those with medicinal products.

Timeline

Start
2020-10-14
Primary completion
2023-01-24
Completion
2023-01-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diclofenac Other / unclassified 3 % Topical

Indications